Indian Journal of Nuclear Medicine

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 37  |  Issue : 2  |  Page : 133--141

Target specific uptake of a newly synthesized radiolabeled 5α-reductase inhibitor “Tc-99m-17-Oxo-17a-Aza-D-Homo-5-Androsten-3β-yl phenoxyacetate (Tc-99m-17a-Aza Steroid)” in rat prostatic neoplastic lesions


Gowsia Jan1, Swati Bhat1, Monika Chauhan2, Devinder Kumar Dhawan3, Neelima Dhingra2, Vijayta Dani Chadha1 
1 Centre for Nuclear Medicine (UIEAST), Panjab University Chandigarh, Chandigarh, India
2 University Institute of Pharmaceutical Sciences, Panjab University Chandigarh, Chandigarh, India
3 Department of Biophysics, Panjab University Chandigarh, Chandigarh, India

Correspondence Address:
Dr. Vijayta Dani Chadha
Center for Nuclear Medicine (UIEAST), Panjab University, Chandigarh - 160 014
India

Objective: Considering the 5α-reductase (5AR) inhibitory activity of the oximes and the importance of the ester group in increasing the anti-androgenic property, we reasoned to synthesize a compound having a lactam group in ring D and an ester group at the 3 β position of the androsterone nucleus. The study aims to radiolabel 17-oxo-17a-aza-D-homo-5-androsten-3β-yl phenoxyacetate (17a-aza steroid) with Tc-99m to evaluate its targeted uptake in experimentally induced prostate carcinogenesis in rats. Materials and Methods: The prediction of the optimal interaction and binding affinity of Tc-99m-17-oxo-17a-aza-D-homo-5-androsten-3 β-ylphenoxyacetate (Tc-99m-17a-aza steroid) toward 5AR inhibitor was done using Biopredicta Vlife MDS tool. Tc-99m-17a-aza steroid was developed by direct radiolabeling protocol. The radio-pharmacological characteristics (serum stability, plasma protein-binding ability, and lipophilicity) of the complex were evaluated. Further, the bio-distribution studies of the complex were performed in rats with experimentally induced prostate carcinogenesis. Results: The in-silico analysis exhibits favorable binding of Tc-99m-17a-aza toward 5AR with D score-130.97. The radiochemical purity of Tc-99m-17a-aza was 96.79%. The radio-complex maintained stability in the rat serum for a period of 6 h (hours). Plasma protein binding and Log Po/w value were observed to be 86.23 ± 7.08% and 0.118 ± 0.045, respectively. A significantly enhanced percent-specific uptake was observed in the prostate of rats with induced prostate carcinogenesis. Conclusion: The study concludes that Tc-99m-17a-aza exhibits prostate specificity and can be explored further for its potential as a radionuclide imaging probe.


How to cite this article:
Jan G, Bhat S, Chauhan M, Dhawan DK, Dhingra N, Chadha VD. Target specific uptake of a newly synthesized radiolabeled 5α-reductase inhibitor “Tc-99m-17-Oxo-17a-Aza-D-Homo-5-Androsten-3β-yl phenoxyacetate (Tc-99m-17a-Aza Steroid)” in rat prostatic neoplastic lesions.Indian J Nucl Med 2022;37:133-141


How to cite this URL:
Jan G, Bhat S, Chauhan M, Dhawan DK, Dhingra N, Chadha VD. Target specific uptake of a newly synthesized radiolabeled 5α-reductase inhibitor “Tc-99m-17-Oxo-17a-Aza-D-Homo-5-Androsten-3β-yl phenoxyacetate (Tc-99m-17a-Aza Steroid)” in rat prostatic neoplastic lesions. Indian J Nucl Med [serial online] 2022 [cited 2022 Aug 12 ];37:133-141
Available from: https://www.ijnm.in/article.asp?issn=0972-3919;year=2022;volume=37;issue=2;spage=133;epage=141;aulast=Jan;type=0